Company
Team
Culture
Honor
R & D
R & D background
R & D pipeline
TISA-818
Montelukast sodium
Intellectual Property
Our focus
ARDS
COPD
SOM
News
Enterprise dynamics
Press report
Development
Recruit
Staff style
Contact
2025-03-13
EnliTISA (Shanghai) Pharmaceutical Co., Ltd. was honored at the Award Ceremony of the 13th China Innovation & Entrepreneurship Competition Finals on December 7, 2024, organized by the Torch High Technology Industry Development Center, Ministry of Industry and Information Technology. The company was recognized on two prestigious lists: • "Best Enterprise in Local Competitions of the 13th China Innovation & Entrepreneurship Competition" • "Top 50 Innovation & Entrepreneurship Enterprises of the 13th China Innovation & Entrepreneurship Competition". The event highlighted outstanding enterprises from 37 regional competitions nationwide, with 1,000 companies advancing to the national stage. EnliTISA’s inclusion reflects its exemplary performance in technological innovation and industrial impact during the competition series.
The 2024 Pudong Innovation & Entrepreneurship Conference, organized by the Shanghai Pudong New Area Economic and Science & Technology Commission, was officially inaugurated at the New Area People’s Government on November 29, 2024.
The 17th Bund Finance · Shanghai International Equity Investment Forum was held in Huangpu on December 10, 2024. With the theme "Invest in Shanghai, Innovate for the Future," the forum gathered top investors, industry experts, entrepreneurs, and innovators to explore collaborative opportunities. EnliTISA (Shanghai) Pharmaceutical Co., Ltd. was selected for the "2024 Shanghai Top 50 Most Investment-Promising Startups" list announced at the event.
From November 19 to 21, 2024, the Bio-medicine National Competition of the 13th China Innovation & Entrepreneurship Grand Prix, organized by the Torch Center of the Ministry of Industry and Information Technology, was successfully concluded. During the event, numerous outstanding enterprises emerged in the bio-medicine field. Among them, EnliTISA (Shanghai) Pharmaceutical Co., Ltd. stood out with exceptional performance and was awarded the "Second Prize in the Bio-medicine National Competition of the 13th China Innovation & Entrepreneurship Grand Prix."
2023-12-26
On November 27, 2023, EnliTISA Pharmaceuticals TISA-818, a Class I innovative drug for the treatment of idiopathic pulmonary fibrosis, was approved by the MPA.
2023-11-25
The Phase II clinical trial of TISA-818-Inj for the treatment of acute respiratory distress syndrome (ARDS) recently completed first patient first visit (FPFV), which was led by Professor Zhan Qingyuan of the China-Japan Friendship Hospital and sponsored by EnliTISA (Shang Hai) Pharmaceutical Co., Ltd (Abbreviated as EnliTISA).
Tel:+86-021-33758853
Add:Room 201, 202, 203, BuildingA, Block1, No. 800, Qingdai Road, Pudong New District, Shanghai
Copyright ©2022 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | SEO 沪ICP备2022023966号-1 Powered by www.300.cn